Adalvo is pleased to announce the successful Marketing Authorization (MA) approval of Pomalidomide Hard Capsules 1/2/3/4mg in Israel.
Our product, based on the reference brand Imnovid, is indicated for the treatment of adult patients with multiple myeloma. Imnovid achieved global sales of approximately $2.6 billion in 2023, with a significant growth potential indicated by a Global 3-year Compound Annual Growth Rate (CAGR) of 7%, according to IQVIA.
With this milestone, Adalvo emerges as a key stakeholder in the Israeli market, offering a cost-effective alternative without compromising on quality.
At Adalvo, we uphold a standard of excellence—there are no half-measures. When your mission is to surpass your competitors, you need a dedicated team driving your vision forward.
Partner with us now!
paulo.rodriguez@adalvo.com – Europe
marta.puig@adalvo.com - South Europe
marc.nolasco@adalvo.com - West Europe
jose.rendueles@adalvo.com- North Europe, CEE & APAC
supreet.sharma@adalvo.com – North America & Canada
camila.reinoso@adalvo.com - LATAM (exc. Brazil)
bruno.alves@adalvo.com - Brazil & MENA
ajish.rajan@adalvo.com – Brands & Specialty Products
arni.baldursson@adalvo.com - Head of Global BD&L
Click on your preferred Business Partner and get in touch today!